|Bid||0.6750 x 2200|
|Ask||0.6830 x 3100|
|Day's Range||0.6401 - 0.7160|
|52 Week Range||0.5500 - 4.6000|
|Beta (5Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jan 12, 2016|
|1y Target Est||3.00|
PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announced the dismissal with prejudice of a consolidated class action lawsuit filed in the United States District Court for the District of Utah under the caption In re PolarityTE, Inc. Securities Litigation, Case No. 2:18-cv-00510. The Court’s order was based on the Company’s motion to dismiss filed on June 3, 2019.
Shares of PolarityTE (NASDAQ:PTE) moved higher by 7.3% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 79.31% over the past year to ($0.18), which beat the estimate of ($0.21).Revenue of $3,337,000 higher by 139.21% from the same period last year, which beat the estimate of $2,970,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.PolarityTE hasn't issued any revenue guidance for the time being.Conference Call Details Date: Nov 09, 2020View more earnings on PTETime: 08:00 AMET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1392187&tp_key=366f166ce8Recent Stock Performance 52-week high: $4.60Company's 52-week low was at $0.78Price action over last quarter: down 32.24%Company Description PolarityTE Inc is a commercial-stage biotechnology and regenerative biomaterials company. Its focused on transforming the lives of patients by discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement or regeneration of skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Tuesday's Pre-Market Session * 12 Healthcare Stocks Moving In Monday's After-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2020. PolarityTE will host a conference call and webcast today, November 9, 2020 at 8:00 a.m. ET.